
Claims

1. A method of preparation of sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4*H*-quinazolin-4-yl]acetate monohydrate of formula (**I**)



(**I**)

comprising the steps:

A-1) providing a suspension of sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)-piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4*H*-quinazolin-4-yl]acetate in diisopropylether,

B-1) stirring the suspension obtained in step A-1 at a temperature in the range of from 40 °C to 60 °C for at least 10 hours, and

C-1) removing the diisopropylether to obtain sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate as a solid,

or, alternatively to steps A-1, B-1 and C-1:

A-2) providing a solution of sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)-piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4*H*-quinazolin-4-yl]acetate in methylene chloride,

B-2) stirring the solution obtained in step A-2 at a temperature in the range of from 40 °C to 60 °C for at least 30 minutes; and

C-2) removing the methylene chloride to obtain sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4*H*-quinazolin-4-yl]acetate monohydrate as a solid.

2. The method according to claim 1, further comprising the subsequent step of heating the sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4*H*-quinazolin-4-yl]acetate monohydrate to a temperature in the range of from 40 °C to 60 °C *in vacuo*.

3. The method according to claim 1, comprising the steps A-1, B-1 and C-1.

4. The method according to claim 1, comprising the steps A-2, B-2, and C-2.

5. The method according to claim 3, wherein in step A-1 the solid/solvent ratio of sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-4*H*-quinazolin-4-yl]acetate in diisopropyl ether is from 10 g/L to 50 g/L.

6. The method according to claim 3 or 5, wherein in step B-1 the suspension of sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate in diisopropylether is stirred at a temperature in the range of from 50 °C to 55 °C, preferably at a temperature of 50 °C for at least 10 hours, preferably for 12 to 18 hours.

7. The method according to any one of claims 3, 5 or 6 wherein in step C-1 the diisopropylether is removed by filtration.

8. The method according to any one of claims 3 or 5 to 7 further comprising the subsequent step of drying the sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate at a temperature in the range of from 20 °C to 60 °C *in vacuo*, preferably for 4 hours or more.

9. The method according to claim 4, wherein in step A-2 the concentration of sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)-phenyl]-4*H*-quinazolin-4-yl]acetate is from 0.5 M to 2 M.


10. The method according to claim 4 or 9, wherein in step B-2 the solution of sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate in methylene chloride is stirred at a temperature in the range

of from 40 °C to 60 °C, preferably at a temperature in the range of from 45 °C to 55 °C for at least 1 hour and then cooled down to room temperature.

11. The method according to any one of claims 4, 9 or 10 , wherein in step C-2 the methylene chloride is removed by evaporation.

12. The method according to any one of claims 4, or 9 to 11, further comprising the subsequent step of drying the sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)-piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate monohydrate at a temperature in the range of from 30 °C to 60 °C *in vacuo*, preferably for 4 hours or more.

13. A crystalline sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4*H*-quinazolin-4-yl]acetate monohydrate of formula (**I**)



(**I**)

.

14. The crystalline sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4*H*-quinazolin-4-yl]acetate monohydrate according to claim 13, having an X-ray diffraction pattern which comprises 2-theta angle values of: 7.0, 9.1, 10.9, 13.3, 14.0, 15.2, 17.4, 18.4, 24.3 degrees, and said 2-theta angle values have a normal deviation of ± 0.1°.

15. The crystalline sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4*H*-quinazolin-4-yl]acetate monohydrate according

to claim 13 or 14 which is obtainable by the method as defined in any one of claims 1 to 12.

16. A pharmaceutical composition comprising the crystalline sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4*H*-quinazolin-4-yl]acetate monohydrate as defined in any one of claims 13 to 15 and at least one pharmaceutically acceptable carrier, excipient and/or diluent.

17. The crystalline sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4*H*-quinazolin-4-yl]acetate monohydrate according to any one of claims 13 to 15 or the pharmaceutical composition according to claim 16 for use in a method of treatment and/or prevention of diseases, in particular of virus infections, preferably human cytomegalovirus (HCMV) infections or infections with another member of the herpes viridae group.

18. Use of the crystalline sodium 2-[(4*S*)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4*H*-quinazolin-4-yl]acetate monohydrate as defined in any one of claims 13 to 15 or the pharmaceutical composition as defined in claim 16 for the preparation of a medicament for the treatment and/or prevention of virus infections.

19. The use according to claim 18, wherein the virus infections are human cytomegalovirus (HCMV) infections or infections with another member of the herpes viridae group.